Chiasma Strengthens Management Team with Announcement of Chief Financial Officer

NEWTON, Mass. and JERUSALEM, May 18, 2015 -- Chiasma, Inc., a U.S. privately held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced the appointment of Mark J. Fitzpatrick as the company's chief financial officer, by June 10, 2015.

"Bringing on Mark as CFO will bolster our leadership team at a critical time in Chiasma's corporate evolution," said Mark Leuchtenberger, chief executive officer of Chiasma. "We look forward to working with Mark as we seek to bring an oral treatment for the acromegaly community closer to reality."

Mr. Fitzpatrick joins Chiasma from Aegerion Pharmaceuticals where he served as CFO since 2011. He has more than 20 years of financial management experience in both public and private companies.

"Having spent many years of my career working in the rare disease space, I am excited about the potential of octreotide capsules to improve the lives of patients with acromegaly," said Mark Fitzpatrick. "I look forward to working with Mark and the Chiasma team as the company continues to grow and mature."

Prior to Aegerion, Mr. Fitzpatrick was vice president, CFO and assistant secretary at Proteon Therapeutics, Inc. and vice president and CFO, treasurer and assistant secretary at RenaMed Biologics, Inc. He also held CFO positions with Dynogen Pharmaceuticals, WorldStreet Corporation and Diacrin. Mr. Fitzpatrick previously was a senior auditor with Arthur Andersen & Co.

Mr. Fitzpatrick earned a Certified Public Accountant certificate in the Commonwealth of Massachusetts in 1987, and holds a B.S. in Accounting from Boston College.

About Octreotide Capsules  

Octreotide capsules are an investigational oral form of the peptide octreotide, a somatostatin analog that is currently available only by injection. Octreotide capsules use a proprietary technology developed by Chiasma, Inc., called Transient Permeability Enhancer (TPE®) that facilitates gastrointestinal absorption of unmodified drug into the bloodstream. Chiasma is independently leading the clinical and regulatory development and commercialization of octreotide capsules for the potential treatment of acromegaly and neuroendocrine tumors.

About Chiasma

Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company's lead product candidate is octreotide capsules for the orphan condition, acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company's TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary.

Additional information can be found at www.ChiasmaPharma.com

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.